US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

UpStream Bio Inc.

8.67

-1.1200-11.44%

Post-market: 8.670.00000.00%18:50 EDT

Volume:939.87K

Turnover:8.20M

Market Cap:471.82M

PE:-3.81

High:9.15

Open:8.72

Low:8.10

Close:9.79

52wk High:33.68

52wk Low:5.14

Shares:54.42M

Float Shares:31.42M

Volume Ratio:0.77

T/O Rate:2.99%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2740

EPS(LYR):-5.5835

ROE:-35.43%

ROA:-23.99%

PB:1.39

PE(LYR):-1.55

Loading ...

Overview Company News Filings

BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score

Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps

Upstream Bio Presents Additional Analyses From the Phase 2 Vibrant Trial of Verekitug in Chronic Rhinosinusitis With Nasal Polyps at 2026 Aaaai Annual Meeting

THOMSON REUTERS

Upstream Bio Inc - Secondary Endpoints Showed Reduction in Nasal Congestion Score by -0.96

THOMSON REUTERS

Arbor Realty Trust Reports Fourth Quarter and Full Year 2025 Results and Declares Dividend of $0.30 per Share

Upstream Bio to Present New Phase 2 VIBRANT Verekitug Analyses at AAAAI Congress 2026 Late-Breaking Poster Session

Upstream Bio CEO Rand Sutherland to Present at TD Cowen Annual Health Care Conference and Leerink Partners Global Healthcare Conference

Press Release: MFA Financial, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Evercore ISI Remains a Buy on Upstream Bio, Inc. (UPB)

Buy Rating on UPB Driven by Tezspire‑Comparable Efficacy, Convenient Q12W Dosing, and Solid Cash Runway Supporting Verekitug’s Long‑Term Potential

BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy

Upstream Bio Reports Mixed Results in Phase 2 Data for Asthma Treatment

Upstream Bio Shares Plunge 20% Premarket After Co Reports Mid-Stage Asthma Drug Trial Data

THOMSON REUTERS

BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold miners

Upstream Bio Reports Positive Phase 2 Severe Asthma Data

BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study

Upstream Bio Inc - Verekitug Well Tolerated With Favorable Safety Profile

THOMSON REUTERS

Upstream Bio Inc - Over 90% of Patients Transitioned to Phase 2 Valour Study

THOMSON REUTERS

Upstream Bio Reports Positive Top-Line Results From the Phase 2 Valiant Trial of Verekitug for the Treatment of Severe Asthma

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/UPB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"UPB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":8.67,"timestamp":1774641600000,"preClose":9.79,"halted":0,"volume":939869,"hourTrading":{"tag":"盘后","latestPrice":8.67,"preClose":8.67,"latestTime":"18:50 EDT","volume":3666,"amount":31781.98,"timestamp":1774651821233,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.11440245148110309,"floatShares":31417476,"shares":54419986,"eps":-2.274,"marketStatus":"Market Closed","change":-1.12,"latestTime":"03-27 16:00:00 EDT","open":8.72,"high":9.15,"low":8.1,"amount":8197973.517216001,"amplitude":0.107252,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.274,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":9.79,"preHourTrading":{"tag":"盘前","latestPrice":8.74,"preClose":9.79,"latestTime":"09:29 EDT","volume":12301,"amount":112605.543578,"timestamp":1774618199999,"change":-1.05,"changeRate":-0.107252,"amplitude":0.127681},"postHourTrading":{"tag":"盘后","latestPrice":8.67,"preClose":8.67,"latestTime":"18:50 EDT","volume":3666,"amount":31781.98,"timestamp":1774651821233,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.772121,"impliedVol":0.4954,"impliedVolPercentile":0.1444},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"UPB\",,,,,undefined,":{"symbol":"UPB","floatShares":31417476,"roa":"-23.99%","roe":"-35.43%","lyrEps":-5.58348,"volumeRatio":0.772121,"shares":54419986,"dividePrice":0,"high":9.15,"amplitude":0.107252,"preClose":9.79,"low":8.1,"week52Low":5.14,"pbRate":"1.39","psRate":"165.32","week52High":33.68,"institutionHeld":0,"latestPrice":8.67,"eps":-2.274,"divideRate":0,"volume":939869,"delay":0,"ttmEps":-2.274,"open":8.72,"prevYearClose":27.15,"prevWeekClose":8.67,"prevMonthClose":7.68,"prevQuarterClose":27.15,"fiveDayClose":8.67,"twentyDayClose":7.68,"sixtyDayClose":27.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/UPB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-26","symbol":"UPB","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"pre","actualEps":-0.79},{"market":"US","date":"2025-05-06","symbol":"UPB","fiscalQuarterEnding":"2025/03","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2025-03-12","symbol":"UPB","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741752000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"UPB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"UPB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.75,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1766030400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/UPB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"UPB","date":"2026-03-27","current":-3.812665,"percent":0.956044,"low":-36.237602,"twenty":-13.665053,"median":-9.577476,"eighty":-7.221038,"high":-3.254005,"avg":-11.441283,"sd":6.820234,"marketCap":532771662},"quantilePoints":[{"date":"2024-10-11","current":-21.547111,"twenty":-21.096119,"median":-20.419631,"eighty":-19.743142,"marketCap":872808815},{"date":"2024-10-18","current":-29.91246,"twenty":-29.856691,"median":-29.151973,"eighty":-22.814588,"marketCap":1211664002},{"date":"2024-10-25","current":-33.154958,"twenty":-33.128498,"median":-29.931472,"eighty":-28.137991,"marketCap":1343007876},{"date":"2024-10-31","current":-32.943274,"twenty":-33.154958,"median":-32.429578,"eighty":-29.151973,"marketCap":1334433205},{"date":"2024-11-08","current":-35.748083,"twenty":-33.28726,"median":-32.943274,"eighty":-29.633615,"marketCap":1448047598},{"date":"2024-11-15","current":-26.036965,"twenty":-33.27403,"median":-32.40745,"eighty":-26.47861,"marketCap":1390295829},{"date":"2024-11-22","current":-17.866537,"twenty":-33.154958,"median":-29.91246,"eighty":-25.555171,"marketCap":954019497},{"date":"2024-11-29","current":-21.951751,"twenty":-33.154958,"median":-29.151973,"eighty":-21.870823,"marketCap":1172157663},{"date":"2024-12-06","current":-22.082237,"twenty":-33.144374,"median":-26.689395,"eighty":-21.903572,"marketCap":1179125222},{"date":"2024-12-13","current":-20.486294,"twenty":-33.088806,"median":-26.036965,"eighty":-21.589777,"marketCap":1093906626},{"date":"2024-12-20","current":-16.672089,"twenty":-32.969734,"median":-24.742143,"eighty":-20.201232,"marketCap":890239542},{"date":"2024-12-27","current":-19.517686,"twenty":-32.858694,"median":-23.382078,"eighty":-19.472518,"marketCap":1042185906},{"date":"2025-01-03","current":-16.36093,"twenty":-32.784605,"median":-22.553994,"eighty":-19.153329,"marketCap":873624596},{"date":"2025-01-10","current":-16.250519,"twenty":-32.617811,"median":-22.077219,"eighty":-18.486847,"marketCap":867728970},{"date":"2025-01-17","current":-10.92067,"twenty":-31.635576,"median":-21.951751,"eighty":-17.320504,"marketCap":583131018},{"date":"2025-01-24","current":-10.810259,"twenty":-29.950484,"median":-21.600443,"eighty":-16.501454,"marketCap":577235392},{"date":"2025-01-31","current":-11.041119,"twenty":-29.91246,"median":-20.852659,"eighty":-16.230444,"marketCap":589562611},{"date":"2025-02-07","current":-8.561886,"twenty":-29.633615,"median":-19.703378,"eighty":-11.472726,"marketCap":457179006},{"date":"2025-02-14","current":-7.3574,"twenty":-29.151973,"median":-19.472518,"eighty":-10.92067,"marketCap":392863085},{"date":"2025-02-21","current":-8.260764,"twenty":-28.137991,"median":-19.276941,"eighty":-10.810259,"marketCap":441100026},{"date":"2025-02-28","current":-7.839194,"twenty":-27.097043,"median":-19.030874,"eighty":-9.965112,"marketCap":418589453},{"date":"2025-03-07","current":-8.451474,"twenty":-26.562924,"median":-18.338294,"eighty":-8.834903,"marketCap":451283380},{"date":"2025-03-14","current":-7.737899,"twenty":-26.318012,"median":-17.866537,"eighty":-8.491624,"marketCap":485986508},{"date":"2025-03-21","current":-6.875286,"twenty":-26.085144,"median":-16.857781,"eighty":-8.411325,"marketCap":431809204},{"date":"2025-03-28","current":-5.816236,"twenty":-26.012875,"median":-16.36093,"eighty":-8.168077,"marketCap":365294494},{"date":"2025-04-04","current":-5.380659,"twenty":-25.645507,"median":-16.240482,"eighty":-7.936302,"marketCap":337937638},{"date":"2025-04-11","current":-5.466066,"twenty":-24.254326,"median":-13.751211,"eighty":-7.734483,"marketCap":343301728},{"date":"2025-04-17","current":-7.191293,"twenty":-23.886958,"median":-11.472726,"eighty":-7.5722,"marketCap":451656335},{"date":"2025-04-25","current":-7.652492,"twenty":-23.286723,"median":-11.041119,"eighty":-7.514132,"marketCap":480622419},{"date":"2025-05-02","current":-7.693506,"twenty":-22.857123,"median":-10.850408,"eighty":-7.502769,"marketCap":483198327},{"date":"2025-05-09","current":-6.005612,"twenty":-22.499792,"median":-10.810259,"eighty":-7.378434,"marketCap":475536334},{"date":"2025-05-16","current":-5.964849,"twenty":-22.162536,"median":-10.288315,"eighty":-7.189481,"marketCap":472308712},{"date":"2025-05-23","current":-6.324914,"twenty":-22.076215,"median":-9.921951,"eighty":-6.77963,"marketCap":500819374},{"date":"2025-05-30","current":-6.352089,"twenty":-22.02402,"median":-9.013568,"eighty":-6.524152,"marketCap":502971123},{"date":"2025-06-06","current":-7.357554,"twenty":-21.951751,"median":-8.668839,"eighty":-6.524152,"marketCap":582585803},{"date":"2025-06-13","current":-7.853492,"twenty":-21.855392,"median":-8.531773,"eighty":-6.551855,"marketCap":621855206},{"date":"2025-06-20","current":-7.228474,"twenty":-21.688772,"median":-8.441437,"eighty":-6.588317,"marketCap":572364999},{"date":"2025-06-27","current":-7.432284,"twenty":-21.589777,"median":-8.421362,"eighty":-6.683973,"marketCap":588503110},{"date":"2025-07-03","current":-7.60892,"twenty":-21.547111,"median":-8.293047,"eighty":-6.875286,"marketCap":602489473},{"date":"2025-07-11","current":-8.043715,"twenty":-21.219023,"median":-8.229183,"eighty":-7.004282,"marketCap":636917443},{"date":"2025-07-18","current":-7.500221,"twenty":-20.486294,"median":-8.00983,"eighty":-7.116503,"marketCap":593882481},{"date":"2025-07-25","current":-9.06956,"twenty":-20.325696,"median":-7.964314,"eighty":-7.165671,"marketCap":718145935},{"date":"2025-08-01","current":-10.401121,"twenty":-19.703378,"median":-8.043715,"eighty":-7.186764,"marketCap":823581592},{"date":"2025-08-08","current":-8.173881,"twenty":-19.517686,"median":-8.19076,"eighty":-7.191293,"marketCap":853925323},{"date":"2025-08-15","current":-9.608438,"twenty":-19.472518,"median":-8.256445,"eighty":-7.228474,"marketCap":1003793530},{"date":"2025-08-22","current":-9.154334,"twenty":-19.472518,"median":-8.332111,"eighty":-7.228474,"marketCap":956353234},{"date":"2025-08-29","current":-8.648626,"twenty":-19.29215,"median":-8.429698,"eighty":-7.242061,"marketCap":903521996},{"date":"2025-09-05","current":-10.155428,"twenty":-19.267816,"median":-8.442215,"eighty":-7.274671,"marketCap":1060937523},{"date":"2025-09-12","current":-9.247219,"twenty":-19.117195,"median":-8.531282,"eighty":-7.282823,"marketCap":966056931},{"date":"2025-09-19","current":-8.911801,"twenty":-19.040911,"median":-8.561886,"eighty":-7.298422,"marketCap":931015804},{"date":"2025-09-26","current":-8.416414,"twenty":-18.814066,"median":-8.561394,"eighty":-7.303028,"marketCap":879262754},{"date":"2025-10-03","current":-9.592957,"twenty":-18.486847,"median":-8.591998,"eighty":-7.324944,"marketCap":1002176247},{"date":"2025-10-10","current":-10.212191,"twenty":-18.290115,"median":-8.630565,"eighty":-7.351996,"marketCap":1066867560},{"date":"2025-10-17","current":-11.4971,"twenty":-18.113457,"median":-8.648626,"eighty":-7.357523,"marketCap":1201102033},{"date":"2025-10-24","current":-10.903668,"twenty":-17.908694,"median":-8.694854,"eighty":-7.362988,"marketCap":1139106192},{"date":"2025-10-31","current":-13.298037,"twenty":-17.320504,"median":-8.903157,"eighty":-7.366819,"marketCap":1389245933},{"date":"2025-11-07","current":-10.460565,"twenty":-17.071577,"median":-8.919541,"eighty":-7.375835,"marketCap":1278553063},{"date":"2025-11-14","current":-10.319087,"twenty":-16.746366,"median":-8.953083,"eighty":-7.3842,"marketCap":1261260713},{"date":"2025-11-21","current":-11.035322,"twenty":-16.535581,"median":-9.042102,"eighty":-7.390371,"marketCap":1348803231},{"date":"2025-11-28","current":-12.644639,"twenty":-16.41714,"median":-9.068084,"eighty":-7.395598,"marketCap":1545503702},{"date":"2025-12-05","current":-12.264416,"twenty":-16.306728,"median":-9.154334,"eighty":-7.402392,"marketCap":1499030514},{"date":"2025-12-12","current":-12.145044,"twenty":-16.258549,"median":-9.253501,"eighty":-7.413262,"marketCap":1484440094},{"date":"2025-12-19","current":-13.201711,"twenty":-16.238474,"median":-9.412348,"eighty":-7.419454,"marketCap":1613592327},{"date":"2025-12-26","current":-13.38298,"twenty":-16.206354,"median":-9.577476,"eighty":-7.422171,"marketCap":1635748149},{"date":"2026-01-02","current":-12.003565,"twenty":-15.686418,"median":-9.608438,"eighty":-7.426849,"marketCap":1467147745},{"date":"2026-01-09","current":-12.175992,"twenty":-13.691713,"median":-9.623919,"eighty":-7.437719,"marketCap":1488222796},{"date":"2026-01-16","current":-13.661516,"twenty":-14.223893,"median":-9.706483,"eighty":-7.459459,"marketCap":1669792461},{"date":"2026-01-23","current":-14.055003,"twenty":-14.055003,"median":-9.763246,"eighty":-7.459459,"marketCap":1717886807},{"date":"2026-01-30","current":-13.679201,"twenty":-14.055003,"median":-9.837934,"eighty":-7.487886,"marketCap":1671954005},{"date":"2026-02-06","current":-11.495127,"twenty":-13.997527,"median":-9.967119,"eighty":-7.498759,"marketCap":1405003366},{"date":"2026-02-13","current":-5.659139,"twenty":-13.966579,"median":-10.045793,"eighty":-7.487886,"marketCap":691693964},{"date":"2026-02-20","current":-3.775707,"twenty":-13.794285,"median":-9.921951,"eighty":-7.430925,"marketCap":461489567},{"date":"2026-02-27","current":-3.49275,"twenty":-13.743121,"median":-9.768407,"eighty":-7.40375,"marketCap":426904868},{"date":"2026-03-06","current":-3.391062,"twenty":-13.712802,"median":-9.724309,"eighty":-7.375835,"marketCap":414475992},{"date":"2026-03-13","current":-4.171405,"twenty":-13.705728,"median":-9.63424,"eighty":-7.351996,"marketCap":509854106},{"date":"2026-03-20","current":-3.704968,"twenty":-13.684506,"median":-9.611018,"eighty":-7.282823,"marketCap":452843392},{"date":"2026-03-27","current":-3.71417,"twenty":-13.665053,"median":-9.577476,"eighty":-7.221038,"marketCap":532771662}],"updateTime":1774751964058},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"UPB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616782016","title":"BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score","url":"https://stock-news.laohu8.com/highlight/detail?id=2616782016","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616782016?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:47","pubTimestamp":1772376426,"startTime":"0","endTime":"0","summary":"BRIEF-Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp ScoreMarch 1 (Reuters) - Upstream Bio Inc UPB.O:UPSTREAM BIO PRESENTS ADDITIONAL ANALYSES FROM THE PHASE 2 VIBRANT TRI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUABNVLKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2616201618","title":"Upstream Bio reports Phase 2 VIBRANT trial gains for verekitug in nasal polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2616201618","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616201618?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376320,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial  evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95  and a reduction in nasal congestion score of -0.96  at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo . These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL3YqRrf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","UPB","LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2616820978","title":"Upstream Bio Presents Additional Analyses From the Phase 2 Vibrant Trial of Verekitug in Chronic Rhinosinusitis With Nasal Polyps at 2026 Aaaai Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2616820978","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616820978?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUABNVLKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2616582016","title":"Upstream Bio Inc - Secondary Endpoints Showed Reduction in Nasal Congestion Score by -0.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2616582016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616582016?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nTUABNVLKV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2614859673","title":"Arbor Realty Trust Reports Fourth Quarter and Full Year 2025 Results and Declares Dividend of $0.30 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859673","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859673?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:30","pubTimestamp":1772199000,"startTime":"0","endTime":"0","summary":"Fourth Quarter Highlights: GAAP net income of $0.07 per diluted common shareDistributable earnings1 of $0.19, or $0.22 per diluted common share, excluding $5.1 million of net realized losses from the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246505/0/en/Arbor-Realty-Trust-Reports-Fourth-Quarter-and-Full-Year-2025-Results-and-Declares-Dividend-of-0-30-per-Share.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","ABR","BK4139","UPB"],"gpt_icon":0},{"id":"2614045110","title":"Upstream Bio to Present New Phase 2 VIBRANT Verekitug Analyses at AAAAI Congress 2026 Late-Breaking Poster Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045110","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045110?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107258,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc. will attend the American Academy of Allergy, Asthma and Immunology  Congress 2026 in Philadelphia, where it will present a late-breaking poster  titled “Efficacy and Safety of Verekitug  in Chronic Rhinosinusitis with Nasal Polyps: Results of the Phase 2 VIBRANT Trial” on Sunday, March 1, 2026  at the Convention Center, Level 2, Hall E.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL8pqyW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2614892720","title":"Upstream Bio CEO Rand Sutherland to Present at TD Cowen Annual Health Care Conference and Leerink Partners Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2614892720","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614892720?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:01","pubTimestamp":1772020874,"startTime":"0","endTime":"0","summary":"Upstream Bio CEO Rand Sutherland to Present at TD Cowen Annual Health Care Conference and Leerink Partners Global Healthcare Conference","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL20hPs3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","IE00BKPKM429.USD","LU2095319765.USD","MNSH","BK4585","SG9999014039.USD","NDAQ","SG9999014021.USD","BK4139","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","BK4207","UPB","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2612461254","title":"Press Release: MFA Financial, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2612461254","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612461254?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:30","pubTimestamp":1771421400,"startTime":"0","endTime":"0","summary":"MFA Financial, Inc.  today provided its financial results for the fourth quarter and full year ended December 31, 2025:. --  MFA generated GAAP net income to common stockholders and participating. securities for the fourth quarter of $43.6 million, or $0.42 per basic. --  Distributable earnings, a non-GAAP financial measure, were $27.8. million, or $0.27 per basic common share. MFA paid a regular cash. dividend of $0.36 per common share on January 30, 2026.Economic book value, a non-GAAP financial measure, was $13.75 per common. --  MFA closed the quarter with unrestricted cash of $213.2 million.$136.5 million, or $1.31 per basic common share and $1.30 per diluted. common share, up from $86.4 million, or $0.83 per basic common share and. \"We continued to execute on our strategic initiatives during the fourth quarter,\" said Craig Knutson, MFA's Chief Executive Officer. \"We acquired $1.2 billion of Agency MBS and $443 million of Non-QM loans, and Lima One originated $226 million of new b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","MFA","BK4110","CRT","UPB","BK4139"],"gpt_icon":0},{"id":"2611698921","title":"Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2611698921","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611698921?lang=en_us&edition=fundamental","pubTime":"2026-02-13 23:45","pubTimestamp":1770997500,"startTime":"0","endTime":"0","summary":"Upstream Bio Inc.  shares are trading lower during Friday’s session as the stock reacts to recent developments in its clinical trials.Over the last few days, the stock has plunged more than 54%.The decline follows a report highlighting the company’s results for its asthma treatment.The VALIANT trial demonstrated statistically significant reductions in the annualized asthma exacerbation rate  of 56% for the 100 mg every 12 weeks dosing compared to placebo.Additionally, the drug showed improvements in lung function and was well-tolerated, with over 90% of eligible patients transitioning to the long-term extension study.The broader market experienced a mixed performance on the previous trading day, with the Healthcare sector remaining flat, gaining 0.00%. Upstream Bio’s decline comes as the broader market showed resilience, suggesting that company-specific factors may be influencing the stock’s movement.Analyst Matt Phipps wrote that shares trading down almost 50% ‘is overdone’, as some i","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Boy-Using-Nasal-Spray-Bottle---Allergy-C.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Boy-Using-Nasal-Spray-Bottle---Allergy-C.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50614440/upstream-bios-selloff-may-be-overdone-but-analyst-highlights-asthma-drugs-competitive-edge-concerns","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50614440/upstream-bios-selloff-may-be-overdone-but-analyst-highlights-asthma-drugs-competitive-edge-concerns","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["TSLP","BK4217","UPB","BK4139","SMA"],"gpt_icon":0},{"id":"2611215711","title":"Evercore ISI Remains a Buy on Upstream Bio, Inc. (UPB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611215711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611215711?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:16","pubTimestamp":1770988611,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Upstream Bio, Inc. yesterday and set a price target of $40.00. Kasimov covers the Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-upstream-bio-inc-upb-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-remains-a-buy-on-upstream-bio-inc-upb-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610153951","title":"Buy Rating on UPB Driven by Tezspire‑Comparable Efficacy, Convenient Q12W Dosing, and Solid Cash Runway Supporting Verekitug’s Long‑Term Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2610153951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610153951?lang=en_us&edition=fundamental","pubTime":"2026-02-11 23:35","pubTimestamp":1770824123,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Kate Dellorusso has maintained their bullish stance on UPB stock, giving a Buy rating today. Kate Dellorusso has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-upb-driven-by-tezspire‑comparable-efficacy-convenient-q12w-dosing-and-solid-cash-runway-supporting-verekitugs-long‑term-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-upb-driven-by-tezspire‑comparable-efficacy-convenient-q12w-dosing-and-solid-cash-runway-supporting-verekitugs-long‑term-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UPB"],"gpt_icon":0},{"id":"2610953407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610953407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610953407?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:04","pubTimestamp":1770818685,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation EnergyEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AU","GFS","HNGE","GILD","AMZW","CDE","THC","HOOG","USAW.SI","SHOP","TPST","TMUS","MRNA","NEM","GLTO","AMZD","HOOD","RIO.AU","NET","AMZY","R","QXO","AMZZ","AVTR","MCD","UPB","MAT","SHPU","KHC","FCX","AMZU","RIO.UK","LYFT","ROBN","BHP.AU","PSN","BETA","AZYY","DTIL","FRSH","HL","CURB","SCCO","HOYY","HUM","AMZN","CEG","HOOW","BWA"],"gpt_icon":0},{"id":"2610144930","title":"Upstream Bio Reports Mixed Results in Phase 2 Data for Asthma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2610144930","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610144930?lang=en_us&edition=fundamental","pubTime":"2026-02-11 21:12","pubTimestamp":1770815520,"startTime":"0","endTime":"0","summary":"Upstream Bio said a Phase 2 clinical trial for its respiratory-disease treatment met its primary endpoint in two dosing regimens, but that a third treatment group didn't see consistent improvements.The clinical-stage biotechnology company said the Phase 2 Valiant clinical trial, evaluating verekitug in adults with severe asthma, showed that verekitug reduced asthma attacks and improved lung function with dosing of 100 milligrams every 12 weeks and 400 mg every 24 weeks.For another low-dose treatment group, 100 milligrams every 24 weeks, Upstream said there were positive effects but not consistent improvements toward the trials' endpoints.Shares were down about 22% to $21.83 in premarket trading.Asthma is a chronic condition in which the airways become inflamed and narrowed, making it hard to breathe.Upstream said it will now use the data collected from the previous trials to inform its decisions for the following phase 3 trial, for which it says planning has already begun.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610320229","title":"Upstream Bio Shares Plunge 20% Premarket After Co Reports Mid-Stage Asthma Drug Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610320229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610320229?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:38","pubTimestamp":1770813532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610932860","title":"BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold miners","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932860","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932860?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:10","pubTimestamp":1770811808,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold minersEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL6N3Z70LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","IE0009356076.USD","LU1814569148.SGD","LU0198837287.USD","LU2324357040.USD","LU2357305700.SGD","LU2097829019.USD","IE0002270589.USD","LU0320765489.SGD","CURB","IE00B3T34201.USD","EXK","FRSH","BK4532","IE0004445015.USD","AMZU","LU0689472784.USD","HOOX","LU1839511570.USD","LU0724618789.USD","LU1267930730.SGD","LU1720051017.SGD","SGXZ51526630.SGD","BK4543","LU2065171311.SGD","BK4122","LU0154236417.USD","LU2023250504.SGD","LU1989764664.SGD","LU1074936037.SGD","LU1232071149.USD","LU0158827948.USD","LU0211328371.USD","BK4116","IE00BQXX3C00.GBP","LU0109394709.USD","LU0061474960.USD","LU0889565833.HKD","BK4583","LU2552382215.SGD","LU0820561818.USD","BK4592","LU1223082519.USD","BK4527","LU0496367417.USD","IE000ITXATA3.USD","AMZY","LU0820562030.AUD","LU0345768740.USD","IE0001KFT4U8.USD","LU1169589451.USD","LU0353189680.USD","LU0787776722.HKD","MCD","LU2471134523.USD","IE000KEQY171.SGD","LU1983260115.SGD","LU0048584097.USD","LU0417517546.SGD","LU2430703095.HKD","BK4548","HK0000914686.HKD","LU1917777945.USD","LU2456880835.USD","BK4501","LU2860962120.EUR","BK4570","IE00B19Z9505.USD","LU1883866441.USD","LU1069344957.HKD","LU0265550946.USD","SG9999014880.SGD","LU1861558580.USD","LU1153585028.USD","LU0265550359.USD","BK4023","LU0107464264.USD","LU1934455277.USD","LU2347655073.USD","IE00BKVL7J92.USD","LU2077746001.SGD","LU1084165304.USD","MAT","LU0072461881.USD","LU0109391861.USD","LU0345770993.USD","LU1223083913.SGD","BK4504","BK4538","LU2430703178.SGD","BK4535","CDE","LU0072462426.USD","SG9999014914.USD","NET","LU1935042488.USD","LU2125154778.USD","HK0000914660.USD","LU0079474960.USD","IE00BWXC8680.SGD","LU0390134368.USD","LU0943347566.SGD","LU1551013342.USD","LU0882574139.USD","BK4139","HOYY","NEM","SG9999014021.USD","SG9999014898.SGD","LU0345780521.USD","LU0985320562.USD","LU2462157665.USD","LU0289739699.SGD","LU0345768153.USD","LU0345770308.USD","LU1861559042.SGD","SG9999015986.USD","BK4522","LU2430703251.USD","LU0234572021.USD","LU0170899867.USD","MRNA","LU0061475181.USD","BK4187","LU2361044865.SGD","IE00B3SWFQ91.USD","LU1035775433.USD","SG9999014013.SGD","LU0210528500.USD","LU1823568750.SGD","LU0640476718.USD","LU1366192091.USD","LU2213496289.HKD","LU1791710582.SGD","BK4613","LU0210536198.USD","LU0965508806.USD","LU1935042215.USD","LU2326559502.SGD","IE000YTNTUN2.SGD","LU2028103732.USD","BK4561","IE00B1BXHZ80.USD","LU0055631609.USD","SG9999017495.SGD","LU2543165471.USD","LU0823434583.USD","LU2065171402.SGD","IE00BSNM7G36.USD","LU1280957306.USD","HODU","LU0215105999.USD","LU0942090050.USD","LU0345769631.USD","LU2756315318.SGD","LU1868836757.USD","BK4607","BK4104","BK4022","LU2168563687.JPY","IE00B19Z8W00.USD","LU1815333072.USD","LU0210533765.USD","LU0724617625.USD","BK4612","LU0345774631.USD","SG9999018865.SGD","SGXZ81514606.USD","LU0127658192.USD","LU2360032135.SGD","LU0368265764.SGD","LU0823421416.USD","GFI","IE00B4JS1V06.HKD","LU1316542783.SGD","LU1323610961.USD","LU2746668974.SGD","LU0965509283.SGD","SG9999001077.SGD","IE00BYQQ9H92.USD","LU2106854487.HKD","LU0612318971.USD","LU1674673691.USD","LU1732799900.SGD","LU2362541273.HKD","LU0342679015.USD","BK4210","LU1429558221.USD","LU0345780950.USD","LU2764262908.HKD","BK4209","BK4231","LU1069347547.HKD","LU0330918003.SGD","LU2381873111.SGD","LU0795875169.SGD","SGXZ23171101.USD","HOOD","LU0130103400.USD","BK4550","LU2247934214.USD","IE00B5949003.HKD","IE00BJTD4N35.SGD","LU0630314457.HKD","IE00BKDWB100.SGD","LU2065169927.USD","LU0889565916.HKD","LU0256863811.USD","LU2317271919.USD","LU0868494708.USD","LU0096364046.USD","IE0005OL40V9.USD","LU2487616109.SGD","IE0003U64NQ7.SGD","BK4560","IE00B5TLWC47.USD","LU0061474705.USD","LU2764263039.SGD","LU0302445910.USD","LU2275660780.HKD","LU0208291251.USD","IE00BMPRXR70.SGD","LU2279689827.SGD","LU0354030438.USD","LU2237957811.SGD","LU1883839398.USD","LU1267930490.SGD","LU1868837136.USD","LU1852331112.SGD","LU1718418525.SGD","LU1066051811.HKD","BK4551","LU2471134952.CNY","LU2462611646.USD","LU2498475776.HKD","IE00B3S45H60.SGD","LU0175139822.USD","LU1093756168.USD","IE0009G5SDU7.USD","LU0308772762.SGD","LU1169590202.USD","LU2065170008.USD","LU0316494557.USD","LU1935042991.SGD","LU2417539215.USD","SG9999002224.SGD","LU0498741890.SGD","LU1046421795.USD","LU1366333091.USD","LU0162691827.USD","LU2211815571.USD","LU0957791311.USD","LU0345774391.USD","BK4554","LU0820561909.HKD","LU2092937148.SGD","LU0612318385.USD","LU2505996681.GBP","IE00BMPRXQ63.HKD","LU2468319806.SGD","LU1145028129.USD","LU1244550577.SGD","LU1066053197.SGD","LU1235294995.USD","GILD","IE00BK4W5L77.USD","LU0823421333.USD","LU0203202063.USD","LU2242650005.HKD","LU1037948541.HKD","LU2361045086.USD","LU2896262040.SGD","BK4578","LU0672654240.SGD","BK4220","IE00BKPKM429.USD","IE00B775SV38.USD","LU0320765059.SGD","LU2461242641.AUD","LU1791710400.SGD","LU1064131342.USD","LU2023251221.USD","LU0654597011.USD","LU1066051498.USD","SG9999015945.SGD","LU0314104364.USD","LU2168564149.EUR","LU1778281490.HKD","LU2362541513.USD","SG9999018857.SGD","LU1093756325.SGD","LU1244550221.USD","LU0053666078.USD","IE00B19Z8X17.USD","LU0075056555.USD","LU2602419157.SGD","LU1066051225.USD","LU2471134796.USD","LU0053671581.USD","LU0965509010.AUD","LU1430594728.SGD","LU0345780281.USD","BK4581","USAW.SI","HOOW","HOOY","LU1988902786.USD","HL","LU1974910355.USD","LU2360106780.USD","LU1633808545.USD","LU2023250330.USD","SG9999000418.SGD","LU1201861165.SGD","LU1035773651.USD","LU0278409577.USD","LU0823434740.USD","SG9999014906.USD","IE00B19Z3581.USD","BK4604","LU2236285917.USD","LU2237957902.USD","IE0004086264.USD","LU0312595415.SGD","LU2505996509.AUD","AMZZ","LU0256863902.USD","LU1023059493.AUD","LU2265009873.SGD","IE00BMPRXN33.USD","LU0266512127.USD","BETA","LU1496350171.SGD","LU1244550494.USD","LU1119994496.HKD","IE000W1ABFV2.USD","LU0056508442.USD","LU1585245621.USD","LU0080751232.USD","LU1430597077.USD","LU0266013472.USD","LU1935043536.SGD","LU0070302665.USD","IE0034235303.USD","BK4190","LU0158827781.USD","LU0234570918.USD","LU0823416689.USD","LU0498741114.HKD","LU0276348264.USD","BK4534","LU2361044949.HKD","IE00B4YYXB79.USD","LU1868836591.USD","LU0029864427.USD","SG9999015978.USD","LU2720916845.USD","LU0082616367.USD","LU2347655156.SGD","LU1868837300.USD","BK4017","LU2592432038.USD","LU1732800096.USD","LU1201861249.SGD","LU1674673428.USD","LU2092627202.USD","AVTR","IE00BJJMRY28.SGD","LU2168564065.EUR","LU0130102774.USD","LU0211331839.USD","LU0077335932.USD","LU0788108826.HKD","LU1934455863.HKD","BK4596","LU0251132253.USD","LU0980610538.SGD","LU2362540622.SGD","IE00BJLML261.HKD","QXO","LU2087621335.USD","BK4524","LU0323591593.USD","LU1548497426.USD","AZYY","LU0097036916.USD","LU1804176565.USD","LU2168564495.EUR","LU2063271972.USD","LU0238689110.USD","HOOG","LU1261432733.SGD","BK4547","LU2264538146.SGD","LU2750360997.AUD","LU0011850046.USD","LU2750360641.GBP","BK4121","BK4585","SG9999001143.SGD","LU0494093205.USD","LU0648001328.SGD","ROBN","LU0345781412.USD","LU0882574055.USD","LU2125154935.USD","BK4230","LU0456854461.SGD","LU1551013425.SGD","IE00BJTD4V19.USD","BK4610","IE00B7SZLL34.SGD","LU0300736062.USD","LU1720051108.HKD","LU2764263203.CNY","BK4097","IE00BFSS7M15.SGD","LU0266512473.USD","LU1571399168.USD","LU2471134879.HKD","LU0345769128.USD","IE0004445239.USD","LU0683600562.USD","LU0965509101.SGD","LU0157215616.USD","IE00BFSS8Q28.SGD","LU2168564222.USD","BK4598","IE00BZ1G4Q59.USD","LU1880398554.USD","LU2552382058.USD","LU2552382132.HKD","LU0528227936.USD","LU0300736492.USD","LU1914381329.SGD","AU","LU2089283258.USD","LU2463028550.USD","SG9999004303.SGD","LU2054465674.USD","UPB","BK4539","LU2089284900.SGD","LU0114720955.EUR","LU1880398471.USD","IE00BK4W5M84.HKD","BK4566","HUM","LU0708995401.HKD","LU0354030511.USD","LU0149725797.USD","IE00B7KXQ091.USD","LU1629891620.HKD","SG9999015952.SGD","IE00B1XK9C88.USD","LU0267386448.USD","LU1496350502.SGD","LU0456855351.SGD","LU0203201768.USD","LU1691799644.USD","LU2089984988.USD","LU2133065610.SGD","LU1435385759.SGD","HOOZ","LU0648000940.SGD","LU1934455194.USD","LU0310800379.SGD","IE00B775H168.HKD","SVM","AMZW","LU2087625088.SGD","LU0708994859.HKD","LU1223082196.USD","LU2250418816.HKD","AMZD","BK4588","LU0289941410.SGD","IE00BQXX3F31.USD","SG9999014005.SGD","IE00BFXG0V08.USD","LU0786609619.USD","LU0058720904.USD","LU2083900584.USD","LU0912757837.SGD","LU1116320737.USD","LU0289960550.SGD","LU1861127337.USD","SBSW","BK4503","SG9999002232.USD","LU0353189763.USD","BK4579","LU2286300806.USD","LU1267930573.SGD","LU2108987350.USD","LU1127390331.HKD","LU0348723411.USD","BK4507","LU2242649171.HKD","LU1935043023.USD","LU2420271590.USD","IE00B19Z3B42.SGD","LU0096362180.USD","LU2237438978.USD","LU0070217475.USD","LU2746668461.USD","LU0466842654.USD","LU0642271901.SGD","LU0788109477.HKD","LU0964807845.USD","LU0861579265.USD","LYFT","LU0128525929.USD","GB00BDT5M118.USD","BK4154","LU0109392836.USD","LU2452424414.USD","LU2403377893.USD","LU0726765562.USD","LU1989764748.USD","LU0719512351.SGD","BK4127","LU2756315664.SGD","IE00BN29S564.USD","SGXZ31699556.SGD","LU1803068979.SGD","LU0795875086.SGD","LU0823411888.USD","IE00BQXX3D17.EUR","LU0320765992.SGD","LU2271345857.HKD","SGXZ99366536.SGD","BK4568","LU0211327993.USD","LU1868836914.USD","LU1116320901.HKD","IE00BJJMRX11.SGD","LU1037948897.HKD","LU0868494617.USD","BK4533","LU0788109121.HKD","LU2211817866.USD","IE0004091025.USD","HOOI","LU2111349929.HKD","LU0310799852.SGD"],"gpt_icon":0},{"id":"2610934931","title":"Upstream Bio Reports Positive Phase 2 Severe Asthma Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2610934931","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610934931?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:58","pubTimestamp":1770811126,"startTime":"0","endTime":"0","summary":"An announcement from Upstream Bio, Inc. ( ($UPB) ) is now available. On February 11, 2026, Upstream Bio reported positive top-line results from its...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/upstream-bio-reports-positive-phase-2-severe-asthma-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/upstream-bio-reports-positive-phase-2-severe-asthma-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610939922","title":"BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610939922","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610939922?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:29","pubTimestamp":1770809384,"startTime":"0","endTime":"0","summary":"BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in midstage study** Shares of drug developer Upstream Bio UPB.O rise 20% to $32.64 in premarket trading** Company says its experimental asthma drug, Verekitug, reduced severe asthma attacks in a midstage study** The drug reduced yearly asthma flareups by 56% at a lower dose and 39% at a higher dose, and improved lung function - UPB** Side-effects were similar to earlier studies; over 90% of eligible patients entered a longterm extension study, company says** UPB plans latestage trials in severe asthma and chronic sinus disease after talks with regulators** Shares up ~65% in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610936578","title":"Upstream Bio Inc - Verekitug Well Tolerated With Favorable Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936578?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2610936506","title":"Upstream Bio Inc - Over 90% of Patients Transitioned to Phase 2 Valour Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936506?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"2610365179","title":"Upstream Bio Reports Positive Top-Line Results From the Phase 2 Valiant Trial of Verekitug for the Treatment of Severe Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610365179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610365179?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:00","pubTimestamp":1770807601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA2GXKFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","UPB"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":67,"code":"91000000","status":"200"}]}}